Quick Answer
Caribou Biosciences, Inc. reported Diluted EPS of $1.59 per share (loss) for fiscal year 2025.
Caribou Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.59 | +3.6% |
| 2024 | -$1.65 | -19.6% |
| 2023 | -$1.38 | +15.9% |
| 2022 | -$1.64 | +22.3% |
| 2021 | -$2.11 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.30 | +21.1% | +48.3% |
| June 30, 2025 | -$0.58 | -38.1% | -34.9% |
| March 31, 2025 | -$0.43 | +6.5% | -13.2% |
| September 30, 2024 | -$0.38 | -216.7% | +9.5% |
| June 30, 2024 | -$0.42 | +12.5% | +8.7% |
| March 31, 2024 | -$0.46 | +0.0% | -283.3% |
| September 30, 2023 | -$0.12 | +72.7% | +75.0% |
| June 30, 2023 | -$0.48 | -9.1% | -4.3% |
- Caribou Biosciences, Inc. showed an increase of +3.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Caribou Biosciences, Inc.’s diluted eps has grown by 24.6% (from $2.11 per share (loss) to $1.59 per share (loss)).
- The most recent figure is from Caribou Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: